Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases and is the fourth leading cause of cancer-related deaths.
1 x 1 Hidalgo, M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605–1617 Crossref | PubMed | Scopus (1493) | Google Scholar See all References Although resection is the best choice for treatment of pancreatic cancer, most cases are diagnosed at late stages, making the patients poor candidates for resection. An explosion in knowledge of the molecular genesis of pancreatic cancer has resulted in definition of PDAC as a cancer with alterations in a wide range of signaling cascades; in contrast, tumorigenesis is driven by a single targetable oncogene in certain tumors.
2 x 2 Jones, S., Zhang, X., Parsons, D.W. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801–1806 Crossref | PubMed | Scopus (2319) | Google Scholar See all References Nonetheless, certain signaling pathways and key nodal points act as core genetic alterations and commonly are detected in PDAC cells. Identifying the mechanisms underlying dysregulation of these core alterations should help the development of innovative strategies for prevention, early detection, and treatment of PDAC.